Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although mutations of the p53 gene have been studied in a wide spectrum of human cancers, GADD45 has not been examined in any tumor or cell line to the best of our knowledge.
|
8834260 |
1996 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reverse transcriptase-polymerase chain reaction and/or Western blotting were used to measure the tumor levels of p53, p21(CDKN1/WAF1) (p21), GADD45, and bcl-2.
|
9406706 |
1997 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The expression of each of the following proteins was significantly associated in the tumours (P < 0.05 unless otherwise stated): Bax with Bcl-2 (P < 0.01); Bax with Mdm2; p21(WAF1/CIP1) with Gadd45 (P < 0.01); p21(WAF1/CIP1) with p53; p53 with Mdm2.
|
11094305 |
2000 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroups of 4-5 mice were sacrificed at 3, 6 and 24 h after therapy so that tumors could be examined for poly(ADP-ribose) polymerase (PARP) and DNA ladder evidence for apoptosis and for BCL2, p53, p21, GADD45, TGF-beta 1 and c-MYC gene and protein expression.
|
11471486 |
2001 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, Gadd45 expression correlated significantly with the grade of the pT factor of the tumors.
|
12171884 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results identify GADD45 as an important mediator for the tumor-suppressing activity of 1,25-dihydroxyvitamin D3 in human ovarian cancer cells.
|
14506229 |
2003 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results indicate that Gadd45a may act as modifier locus for T-cell LBL, whereby deletion of Gadd45a enhances development of this tumor type in susceptible mice.
|
15744335 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression analysis of cell-cycle regulatory genes in rapamycin-treated human lymphoblastoid cells indicated that rapamycin decreased the expression of the tumor suppressor gene GADD45.
|
15920752 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We chose the GADD45A and EPB41 genes as tumor suppressor candidates based on their function and chromosomal localization.
|
16157202 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The combined consideration of TP and GADD45 gene expression, showed the most obvious association with therapy response in this tumor.
|
17163161 |
2006 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The significant decrease in Gadd45 expression in tumors compared with normal tissue and its association with histological grading suggest a role for Gadd45 in the differentiation pathway of NSCLC.
|
16827157 |
2006 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To date, defects of the GADD45 gene family have not been implicated in osteosarcoma (OS) oncogenesis, and the role of this pathway in regulating apoptosis in this tumor is unknown.
|
18472964 |
2008 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was significant upregulation in expression of CDK4 (p<0.01) and downregulation in expression of GADD45A (p<0.001) in the tumour tissue when compared with macroscopically normal mucosa.
|
18978177 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gadd45alpha is one of the growth arrest and DNA damage-inducible (Gadd) 45 gene family members and serves as a stress sensor and tumor suppressor under most stress conditions, which is evidenced by cell cycle arrest, DNA repair, senescence or apoptosis triggered by induction of GADD45alpha expression.
|
19689359 |
2009 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although deregulation of GADD45 expression has been reported in several types of human tumors, its role in lung cancer is still unknown.
|
20652500 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging functional evidence implies that GADD45 proteins serve as tumor suppressors in response to diverse stimuli, connecting multiple cell signaling modules.
|
22515981 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
GADD45a mRNA and protein levels were increased significantly in tumor tissue than that in adjacent normal tissue.
|
22313682 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
An overriding theme is that each of the gadd45 genes has both tumor suppressor and tumor promoter functions, dependent on the tissue/cell type and transforming event.
|
24104471 |
2013 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of Gadd45a was significantly associated with lymph node metastasis, tumor stage and tumor histological grade (P < 0.05).
|
25450267 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the PCF-mediated substantial increase in GADD45a expression indicated that PCF promoted demethylation of tumour suppressor genes via GADD45a induction.
|
25392149 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These data suggest that GADD45A (1506T>C) is a new tumor susceptibility gene and could be a useful molecular marker for assessing ovarian cancer risk and for predicting ovarian cancer patient prognosis.
|
26422378 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Ectopic ABCE1 expression promoted clonogenicity and anchorage-independent growth of LTEP-a-2 cells, while in a mouse xenograft tumor model, it had an augmentative effect on tumor growth and metastasis and reduced the expression of the tumor-suppressor gene growth arrest and DNA damage-inducible 45α (GADD45α).
|
26733164 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RA induces the partnering between retinoic acid receptor (RAR) and tumor suppressor inhibitor of growth protein 1 (ING1), which prevents the formation of GADD45A and ING1 complex necessary for locus-specific Zfp423 DNA demethylation.
|
28992291 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gadd45a is a key component protecting skin against UV-induced tumors.
|
29663367 |
2018 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor biopsies were taken prior to the start of neoadjuvant therapy for expression of EGFR, Her-2-Neu, and GADD45 by immunohistochemistry and for HPV by PCR.
|
29386013 |
2018 |